PCM
ELVN icon

Prelude Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Prelude Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,578
Closed -$2.06M – 1318
2026
Q1 		$2.06M Hold
52,578
– – 0.16% 163
2025
Q4 		$810K Buy
+52,578
New +$1.05M 0.06% 371
2024
Q2 		– Sell
-12,484
Closed -$220K – 1294
2024
Q1 		$220K Buy
+12,484
New +$192K 0.01% 1061
2023
Q3 		– Sell
-33,550
Closed -$26.8K – 1188
2023
Q2 		$26.8K Sell
33,550
-512
-2% -$10.3K ﹤0.01% 1004
2023
Q1 		$40K Buy
34,062
+18,776
+123% +$382K ﹤0.01% 1014
2022
Q4 		$250K Buy
+15,286
New +$244K 0.01% 878
2022
Q2 		– Sell
-4,886
Closed -$37K – 1872
2022
Q1 		$37K Buy
4,886
+175
+4% +$1.15K ﹤0.01% 1506
2021
Q4 		$42K Buy
+4,711
New +$61.8K ﹤0.01% 1792
2020
Q2 		– Sell
-476
Closed -$31K – 2028
2020
Q1 		$31K Buy
+476
New +$30.3K ﹤0.01% 873

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Prelude Capital Management's ELVN Position: Q2 2026 in Review

Prelude Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 52,578 shares — an estimated $2.06M sold.

Prelude Capital Management first reported a position in ELVN in Q1 2020 and held it in 9 quarters. The position peaked at $2.06M in Q1 2026. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Prelude Capital Management reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 52,578 Enliven Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Prelude Capital Management first reported a position in Enliven Therapeutics in Q1 2020 and held it in 9 quarters.
  • Prelude Capital Management's Enliven Therapeutics position peaked at $2.06M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.